Medical Biomaterials News
-
Alfa Chemistry Recently Launched a Sub-website for Functional Polymers
The US-based chemical supplier Alfa Chemistry announced the launch of a new sub-website for the supply of functional polymers, including Adsorptive Polymers, Biomedical Polymers, Electrofunctional Polymers, Functional PEGs, Photoactive Polymers, Silicone Polymers and more. With unstopping efforts, the company continues to offer chemicals for specialized applications, such as catalysts, fatty ...
-
Alfa Chemistry Shines as a Premier Recombinant Human Collagen Product Supplier
In the field of regenerative medicine and tissue engineering, the demand for collagen-based biomaterials is rapidly increasing. Collagen, the most abundant protein in the human body, plays a crucial role in maintaining the structure and function of various tissues. Recognizing the growing need for high-quality collagen products, Alfa Chemistry has emerged as a reliable supplier of recombinant ...
-
CD Bioparticles Announces Expanded Offerings of Polydimethylsiloxane for Cutting-Edge Research
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced an expanded portfolio of Polydimethylsiloxane (PDMS) products, empowering researchers with versatile and biocompatible tools for groundbreaking discoveries. Polydimethylsiloxane is an elastomeric polymer with interesting properties for biomedical applications, including ...
-
Matexcel Provides Expansive Array of Bio-ink Products for Different Applications
Matexcel, a leading innovator in advanced materials and bioengineering, today announced its diverse portfolio of bio-ink products, empowering researchers across various fields to unlock the potential of 3D bioprinting. This comprehensive range, featuring tailored bio-inks for specific applications, paves the way for revolutionary advancements in regenerative medicine, drug discovery, and beyond. ...
By Matexcel
-
The European Commission requests a second scientific opinion on Hydroxyapatite (nano) based on new evidence provided by industry
Following a previous SCCS conclusion on the safety of Hydroxyapatite (nano) when used at concentrations up to 10 % in toothpaste, and up to 0.465 % in mouthwash regarding rod-shaped Hydroxyapatite (nano) particles (see SCCS opinion Hydroxyapatite March 2023), industry has provided new evidence on the safety of Hydroxyapatite (nano) which now has turned into a new opinion ...
-
CELLINK and Ossiform Enter a Strategic Partnership to launch Ossi Ink, a printable bioink based on Ossiform’s P3D Bone material
CELLINK and Ossiform have entered a strategic partnership to join forces to commercialize a ready-to-print bioink based on Ossiform’s existing biomaterial. Sales of the material will begin in 2024 and will be distributed co-exclusively through CELLINK’s commercial channels. Bone regeneration is one of the fastest growing research disciplines, given the massive impact it can have on ...
By CELLINK
-
Empowering Research Excellence: Alfa Chemistry's THEIC, D-Pantethine, and Methoxytriethyleneoxypropyltrimethoxysilane at the Forefront
In the realm of scientific research, the pursuit of excellence is often driven by the quest for innovative solutions and groundbreaking discoveries. Alfa Chemistry, a leading global supplier of research chemicals, has been at the forefront of empowering researchers with the highest quality products. Among the newest additions to its extensive catalog are THEIC, D-Pantethine, and ...
-
CELLINK and the University of California, San Diego Partner to Open a 3D Bioprinting Centre of Excellence
CELLINK, a leading global provider of bioprinting technologies, and the University of California, San Diego (UCSD), a world-renowned research institution, are pleased to announce their partnership to establish a 3D bioprinting Centre of Excellence. This partnership aims to facilitate the utilization of advanced bioprinting technologies and promote cutting-edge research in the fields of drug ...
By CELLINK
-
Alfa Chemistry Offers Varieties of Marine Biomaterials for Use in Biomedicine, Cosmetics and Nutraceuticals
The US-located chemical supplier Alfa Chemistry has recently unveiled its wide range of marine biomaterials, opening new possibilities in the fields of biomedicine, cosmetics, and nutraceuticals. With an extensive collection of marine polysaccharides, oligosaccharides, bioactive peptides, marine oils, and microalgae powders, researchers and industries alike can explore the potential of marine ...
-
LaunchPad Medical Wins a $2.5 Million NIH Grant to Improve Cranial Procedures
LaunchPad Medical, Inc. announced that it has been awarded a $2.5 million Direct-to-Phase II Small Business Innovation Research (SBIR) grant (1R44NS115386) from the National Institute of Neurological Disorders and Stroke to advance the development of Tetranite®, its bone adhesive biomaterial technology, to improve cranial flap fixation procedures. The clinical use of this product is expected ...
By RevBio Inc.
-
RevBio Receives NIH Grant to Explore the Treatment of Vertebral Compression Fractures with Its Regenerative Bone Adhesive Technology
RevBio, Inc., announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute on Aging, part of the National Institutes of Health. This funding will allow the company to pursue the treatment of vertebral compression fractures with its patented bone adhesive technology known as Tetranite®. Because the osteoconductive bone adhesive is ...
By RevBio Inc.
-
Lattice Medical announces the success of the first breast reconstruction operation with the Mattisse implant
After the entry into clinical phase announced in early July 2022, LATTICE MEDICAL, announces the success of the first breast reconstruction operation with the MATTISSE implant. The operation took place on July 12 at the Institute of Clinical Oncology, Tbilisi, Georgia. It was conducted by Pr Gia Nemsdaze and his team, and in the presence of the co-founders of Lattice Medical, Pr. Pierre ...
-
RevBio Receives Approval from the U.K.’s Regulatory Authority to Initiate a Clinical Trial for an Optimized Formulation of its Dental Bone Adhesive Biomaterial
RevBio, Inc., announced that it has received approval from the Medicines and Healthcare products Regulatory Agency in the United Kingdom to start a 15-patient clinical trial to examine the safety and efficacy of immediately stabilized dental implants following tooth extractions using an optimized formulation of Tetranite®, the company’s bone adhesive biomaterial. Dr. Michael R. Norton, ...
By RevBio Inc.
-
Defymed at the annual conference of the European Society for Biomaterials (ESB)
4-8 September: Defymed at the annual conference of the European Society for Biomaterials (ESB). Elisa MAILLARD PEDRACINI, our Chief Scientific Officer and Charles-Thibault BURCEZ, our Chief Product Officer will be present from the 4th to the 9th of September at the annual conference of the European Society for Biomaterials (ESB). The theme of this 32nd edition is “Innovative Biomaterials ...
By Defymed
-
Celularity Presents Preclinical Data on Allogeneic Genetically-Modified Natural Killer Cells at the Society for Immunotherapy of Cancer 36th Annual Meeting
Celularity Inc. (Nasdaq: CELU) (“Celularity”) presented preclinical data on the development of its novel allogeneic genetically modified human placental CD34+ derived NK cell therapeutic program CYNK-101. Celularity reported its findings in a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting held in Washington, D.C., November 10-14, 2021. Poster ...
-
Celularity to be Added to the Russell 3000 Index and The Small-Cap Russell 2000
Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced it is set to join the broad-market Russell 3000 and the Russell 2000 Indexes at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the U.S. market opens on June 27, 2022 ...
-
Celularity Appoints Industry Leader Diane Parks to its Board of Directors
Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an executive with deep experience in the commercialization of novel immuno-oncology therapies, has led the successful launch of numerous ...
-
Lineage Broadens Collaboration With Advanced BioMatrix for HyStem Cell Drug Delivery Technology
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it has expanded its existing collaboration with Advanced BioMatrix, a division of BICO Group AB (STO: BICO), for Lineage’s HyStem cell/drug delivery technology. Under the expanded collaboration, Advanced ...
-
CD Bioparticles Introduces the Launch of Alginates for Drug Delivery Research
CD Bioparticles, a leading manufacturer and supplier of various drug delivery products and services, now introduces a series of alginates products to support drug delivery research. They can be labeled with biotin or functionalized with amine groups, and are for laboratory research use only. Alginates are natural polymers composed of linear copolymers of ß-(1-4)-linked d-mannuronic acid and ...
-
Celularity Inc. Announces $30 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 4,054,055 shares of its Class A common stock at a purchase price of $7.40 ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you